Cervical Cancer
A highly preventable cancer of the lower uterus caused by HPV, characterized by abnormal bleeding, and treated with surgery or radiation.
Emergency Management: Massive vaginal bleeding from tumor erosion requires emergent vaginal packing, tranexamic acid, and sometimes urgent embolization of the uterine arteries or palliative radiation to control the hemorrhage.
Cervical cancer is a malignancy arising from the cervix, the lower part of the uterus that opens into the vagina. It is almost exclusively caused by persistent infection with high-risk human papillomavirus (HPV). The disease progresses slowly from precancerous lesions (cervical intraepithelial neoplasia, CIN) to invasive cancer, making it highly preventable through screening and vaccination.
Detailed Overview
Squamous cell carcinoma accounts for roughly 80% of cases, while adenocarcinoma makes up most of the remainder. Early-stage cervical cancer is typically asymptomatic, underscoring the vital role of routine Pap smears and primary HPV testing. When symptoms do occur, abnormal vaginal bleeding—particularly postcoital bleeding—is the classic presentation. Treatment ranges from fertility-sparing excisional procedures for early disease to radical hysterectomy or concurrent chemoradiation for more advanced stages. Unlike many other cancers, cervical cancer staging is heavily clinical, incorporating physical examination and basic imaging.
Epidemiology & Demographics
Worldwide, it is the 4th most common cancer in women. Incidence is drastically lower in countries with established screening programs. In the US, there are about 14,000 new cases annually. It primarily affects women between ages 35 and 44.
Etiological Mechanism
Persistent, chronic infection with high-risk strains of Human Papillomavirus (HPV). HPV types 16 and 18 are responsible for approximately 70% of all cervical cancers.
Primary Causes
HPV infection acquired through sexual contact. The virus infects the basal cells of the cervical transformation zone. In a minority of women, the immune system fails to clear the virus, leading to chronic infection and oncogenesis.
High-risk HPV integrates its circular double-stranded DNA into the host cell genome. This integration disrupts the viral E2 gene, leading to uninhibited expression of viral oncoproteins E6 and E7. E6 binds to and degrades the host TP53 tumor suppressor protein, preventing apoptosis. E7 binds to and inactivates the host Retinoblastoma (Rb) protein, pushing the cell inappropriately into the S-phase of the cell cycle. The resulting uncontrolled cellular proliferation leads to dysplasia (CIN 1 to CIN 3) and eventually breaches the basement membrane to become invasive carcinoma, spreading locally to the vagina, parametrium, and pelvic sidewall, and metastasizing via lymphatics.
Diagnostic Criteria & Guidelines
Diagnosis is confirmed via a tissue biopsy. Abnormal screening (Pap/HPV) leads to colposcopy, where acetic acid is applied to highlight acetowhite changes, allowing for targeted punch biopsies. If invasive cancer is suspected, a larger biopsy or LEEP is performed.
For early-stage disease (Stage IA - IB1): Surgical management is preferred. Radical Hysterectomy with pelvic lymph node dissection. For young women desiring fertility preservation with very early disease, a Radical Trachelectomy or Cone Biopsy may be performed. For locally advanced disease (Stage IB3 - IVA): Primary definitive treatment is concurrent Chemoradiation. External Beam Radiation Therapy (EBRT) + Brachytherapy, given alongside weekly Cisplatin (40 mg/m2) to act as a radiosensitizer.
Second-Line & Adjunctive Therapy
For recurrent or metastatic disease (Stage IVB): Systemic palliative chemotherapy. Standard regimen is Cisplatin/Paclitaxel combined with Bevacizumab (an anti-VEGF targeted antibody). Pembrolizumab (immunotherapy) is added if the tumor expresses PD-L1.
Surgical & Procedural Management
Radical Hysterectomy involves removing the uterus, cervix, upper vagina, and parametrial tissues. Pelvic exenteration is a massive salvage surgery reserved for central pelvic recurrence after radiation, involving removal of the bladder, rectum, and reproductive organs.
Patient Counseling & Advice
Educate the patient that treatment (surgery or radiation) will result in infertility and may cause sexual dysfunction (vaginal stenosis, dryness). Provide psychological support due to the profound impact on body image and reproductive capabilities.
Follow-Up & Monitoring Schedule
History, physical exam, and vault cytology (Pap smear of the surgical stump) every 3-6 months for 2 years, then every 6-12 months for 3 years, then annually. Monitor closely for leg swelling or localized pain indicating recurrence.
Preventive Strategies
HPV Vaccination: The 9-valent HPV vaccine (Gardasil 9) given to boys and girls starting at age 11-12 prevents infection from the strains causing 90% of cancers. Secondary prevention via screening: Pap smear alone every 3 years (ages 21-29), then HPV co-testing every 5 years (ages 30-65).
Highly stage-dependent. 5-year survival for localized early stage is >90%. For regional disease treated with chemoradiation, it is ~60%. For metastatic disease, it drops to ~17%.